Gerardo Ferbeyre, a research member at the Institute, and Sebastian Igelmann, a doctoral student in his laboratory and first author of the study, have made a discovery that opens a new avenue for potential cancer therapies. The two scientists published a study in Molecular Cell showing that an enzyme complex called HTC (hydride transfer complex) can inhibit cell aging.
When cells age, a state called “cellular senescence” occurs and cells stop dividing. HTC, composed of three enzymes, may be a potential target for stopping the growth of cancer cells in certain types of cancer, including prostate cancer.
Colorectal Cancer: The Impact of the Microbiota on Post-Surgery Healing
9 January 2024
Dr. Roy Hajjar, a resident in general surgery and a member of the Montreal Cancer Institute community, has published a […]
John Stagg : From Lab to Clinic
16 November 2023
Institute Research Member, John Stagg, and his team’s work on pancreatic cancer has led to a clinical study by Trishula […]